Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Suki Shergill"'
Autor:
Ion Agirrezabal, Luiz Sérgio Pereira Grillo Junior, Felipe Nasser, Victoria K. Brennan, Diogo Bugano, Francisco Leonardo Galastri, André Luis F. de Azeredo- da-Silva, Suki Shergill, Joaquim Maurício da Motta-Leal-Filho
Aims Hepatocellular carcinoma (HCC) is a severe condition with poor prognosis that places a significant burden on patients, caregivers, and healthcare systems. Selective internal radiation therapy (SIRT) is a treatment available to patients with HCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c553fa45f17118051a636f7ca5d95ba
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Background and Aims Quality of life is among the most important considerations in the treatment of hepatocellular carcinoma (HCC), arguably second only to overall survival. Measuring and modeling patient quality of life is also crucial in the evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2e217ae9ec4b8533411b932416c3328
http://europepmc.org/articles/PMC8473933
http://europepmc.org/articles/PMC8473933
Autor:
Richard F. Pollock, Suki Shergill, Phuong Lien Carion, Nanette von Oppen, Ion Agirrezabal, Victoria K. Brennan
Publikováno v:
Advances in therapy.
Selective internal radiation therapy (SIRT) is a targeted method of treatment for unresectable liver tumors in which radiation therapy is directly delivered to the tumor(s) via the hepatic vasculature. Successful outcomes with SIRT are dependent on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b449b738e5be4cad5c5585b39c2c24b
https://pubmed.ncbi.nlm.nih.gov/36318388
https://pubmed.ncbi.nlm.nih.gov/36318388
Autor:
Damian Mullan, Rachel Evans, Paul Ross, Noemi Muszbek, Victoria K Brennan, Edit Remak, Fabien Colaone, Suki Shergill
Publikováno v:
Future Oncology. 17:1055-1068
Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Mat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9973c89072ad225970e2c251dd7ab6
https://doi.org/10.2217/fon-2020-1004
https://doi.org/10.2217/fon-2020-1004
Autor:
Ion Agirrezabal, Victoria K. Brennan, Fabien Colaone, Suki Shergill, Helena Pereira, Gilles Chatellier, Valérie Vilgrain
Publikováno v:
Advances in therapy. 39(5)
Given the relatively short life expectancy of patients with hepatocellular carcinoma (HCC), quality of life (QOL) plays a significant role in treatment selection. This analysis aimed to compare time to deterioration (TTD) in QOL with transarterial ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf8db3555b884d9e2a972c3bfac0a970
https://pubmed.ncbi.nlm.nih.gov/35279814
https://pubmed.ncbi.nlm.nih.gov/35279814
Autor:
Edit Remak, Damian Mullan, Paul Ross, Noemi Muszbek, Rachel Evans, Fabien Colaone, Victoria K Brennan, Suki Shergill
INTRODUCTION While essential for cost-effectiveness analyses, there are no current resource use and cost data available for advanced hepatocellular carcinoma (HCC) and selective internal radiation therapy (SIRT). The study aims to assess current reso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60db0050c67f619ffcd4d12bd26a6b02
Publikováno v:
International Journal of Technology Assessment in Health Care. 38:S101-S101
IntroductionThere were an estimated 55,102 new cases of colorectal cancer (CRC) in Brazil in 2020, comprising 9.3 percent of all newly diagnosed cancers, and making it the third most common cancer in the Brazilian population. Up to half of all patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35fa50dc3ebd6310e7a30a67e6792d8f
https://doi.org/10.1017/s0266462322002914
https://doi.org/10.1017/s0266462322002914
Autor:
Siu Hing Lo, Fabien Colaone, Ion Agirrezabal, Vincenzo A Straccia, Andrew J Lloyd, Daniel Aggio, Victoria K Brennan, Rohini Sharma, Suki Shergill, Charlotte E Costentin
The present study aimed to explore patient preferences for attributes of advanced hepatocellular carcinoma (HCC) treatments. A stated preference survey was completed by 150 patients with HCC living in Europe. Overall survival (OS) was the most import
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4614cf28a0432cd28104a4b19a0806dd
http://hdl.handle.net/10044/1/91181
http://hdl.handle.net/10044/1/91181
Publikováno v:
Expert review of anticancer therapy. 21(3)
Background Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. First-line treatment options for unresectable HCC include sorafenib, lenvatinib, selective internal radiation therapy (SIRT), and transarterial chemoembolizati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d0b7cf19e31568145359c558cb7a11
https://pubmed.ncbi.nlm.nih.gov/33131346
https://pubmed.ncbi.nlm.nih.gov/33131346
Publikováno v:
Journal of medical economics. 23(12)
Limited treatment options are available in chemotherapy-refractory or -intolerant metastatic colorectal cancer (mCRC). The objective of the present analysis was to evaluate the cost-utility of SIR-Spheres Y-90 resin microspheres relative to best supp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::540b3eca238e1d7fcbc491bdf99faa80
https://pubmed.ncbi.nlm.nih.gov/33084466
https://pubmed.ncbi.nlm.nih.gov/33084466